Aptose Biosciences Files 8-K on Shareholder Vote Matters

Ticker: APTOF · Form: 8-K · Filed: Sep 6, 2024 · CIK: 882361

Sentiment: neutral

Topics: corporate-governance, shareholder-meeting

TL;DR

Aptose Biosciences held a shareholder vote; expect news soon.

AI Summary

Aptose Biosciences Inc. filed an 8-K on September 6, 2024, reporting on matters submitted to a vote of its security holders as of September 5, 2024. The filing details the company's corporate structure, including its former names and dates of name changes, and provides its business and mailing addresses in Toronto, Canada.

Why It Matters

This filing indicates that Aptose Biosciences held a shareholder vote, which could lead to significant corporate decisions or changes that impact the company's direction and its investors.

Risk Assessment

Risk Level: medium — Shareholder votes can result in changes to company leadership, strategy, or financial structure, introducing uncertainty.

Key Players & Entities

FAQ

What specific matters were submitted to a vote of Aptose Biosciences' security holders?

The filing states it is a "CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934" and that the "Date of Report (Date of earliest event reported): September 5, 2024" pertains to "Submission of Matters to a Vote of Security Holders." However, the specific details of these matters are not provided in the excerpt.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on September 5, 2024.

What is the primary business of Aptose Biosciences Inc. according to the filing?

According to the filing, Aptose Biosciences Inc. is in the business of "BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]".

Where is Aptose Biosciences Inc. headquartered?

Aptose Biosciences Inc.'s business and mailing addresses are located in Toronto, Canada.

What were some of Aptose Biosciences Inc.'s former company names?

Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc.

Filing Stats: 577 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-09-06 16:15:12

Filing Documents

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. On September 5, 2024, Aptose Biosciences Inc., or the "Corporation," held a Special Meeting of Shareholders. At the meeting, shareholders voted in favor of all items of business, as indicated below: Proposal No. 1-Authorization Of The Issuance Of Warrant Shares Underlying Certain Warrants The Corporation's shareholders voted to authorize, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of Warrant Shares in an amount equal to or in excess of 20% of the Shares outstanding immediately prior the issuance of such warrants issued pursuant to that certain securities purchase agreement dated as of May 30, 2024 by and among the Corporation and certain institutional and accredited investors in connection with the Corporation's registered direct offering and private placement which closed on June 3, 2024. Votes For % Votes For Vote Against % Votes Against Abstain Broker Non- Votes 5,769,105 95.32% 267,013 4.41% 16,342 0 Proposal No. 2-Meeting Adjournment The Corporation's shareholders voted to approve a resolution permitting the adjournment of the meeting, if necessary or appropriate, to solicit additional proxies in the event there are not sufficient votes to approve Proposal No. 1. Votes For % Votes For Vote Against % Votes Against Abstain Broker Non- Votes 5,873,779 97.05% 138,958 2.30% 39,722 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: September 6, 2024 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing